10
Participants
Start Date
November 30, 2007
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
doxorubicin and bortezomib
Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
UPMC Cancer Center - Beaver, Beaver
UPMC Cancer Center - Clairton, Clairton
UPMC Cancer Center -Wexford, Wexford
UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group, Moon Township
UPMC Cancer Center - McKeesport, McKeesport
UPMC Cancer Center -Haymaker Rd., Monroeville
UPMC Cancer Center -Mosside Blvd., Monroeville
UPMC Cancer Center -Delafield Rd., Pittsburgh
UPMC Cancer Center - Mercy, Pittsburgh
University of Pittsburgh Cancer Institute-Hillman Cancer Center, Pittsburgh
UPMC Cancer Center - Passavant, Pittsburgh
UPMC Cancer Center -Drake, Pittsburgh
UPMC Cancer Center - Washington, Washington
UPMC Cancer Center - Uniontown, Uniontown
UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg, Greensburg
UPMC Cancer Center - Oakbrook Commons - Greensburg, Greensburg
UPMC Cancer Center -Mt. Pleasant, Mount Pleasant
UPMC Cancer Center - Indiana, Indiana
UPMC Cancer Center - John P. Murtha Pavilion - Johnstown, Johnstown
UPMC Cancer Center -New Castle, New Castle
UPMC Cancer Center - Teramana Cancer Center - Steubenville, Steubenville
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Pittsburgh
OTHER